Lilly Acquires Ventyx Biosciences for $1.2 Billion to Expand Inflammation Treatment Pipeline
Eli Lilly acquires Ventyx Biosciences for $1.2 billion to advance oral therapies targeting chronic inflammation in heart, brain, and autoimmune diseases.
/ 111 items
#LLY↓
Arrowhead Gene Drug Doubles Weight Loss in Obesity Trial
Arrowhead Pharmaceuticals' (ARWR) ARO-INHBE gene-silencing drug combined with Zepbound doubles weight loss in obese diabetes patients, targeting dangerous visceral and liver fat more effectively.
Novo Nordisk Launches Wegovy Weight-Loss Pill in the U.S.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
Novo Nordisk Slashes Wegovy Prices in China by 50%
Novo Nordisk cuts Wegovy obesity drug prices by half in Chinese provinces as patent expiration looms and local competitors prepare cheaper alternatives.
Eli Lilly Eyes French Biotech Abivax for Ulcerative Colitis Drug Deal
Pharma giant Eli Lilly considers acquiring French biotech Abivax for its promising ulcerative colitis treatment, expected to launch in 2027.
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.